Meloxicam Tablet
Product Images NDC 31722-227

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 31722-227). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

15-100 (15 100)

Label for Meloxicam Tablets USP 15 mg by Camber Pharmaceuticals, Inc. The label includes dosage strength (15 mg), quantity (100 tablets), and storage instructions. It states the medication is prescription only, provides directions for pharmacists to dispense an attached Medication Guide, and lists the manufacturers and locations. The label also features a barcode and temperature storage guidelines.*

FDA Label Image

15-1000 (15 1000)

Meloxicam 15 mg Tablets USP oral dosage form label from Camber Pharmaceuticals, Inc. The label indicates 1000 tablets in the package, with storage instructions between 20° to 25°C, and includes a Pharmacist note to dispense the attached Medication Guide. It is marked Rx Only and contains manufacturer and distributor information.*

FDA Label Image

15-500 (15 500)

Meloxicam 15 mg tablets USP label from Camber Pharmaceuticals, Inc. The label indicates 500 tablets in the package. It includes directions to dispense the attached Medication Guide to each patient, storage instructions at 20 to 25 degrees Celsius, and safety notes. The label features the Camber logo, NDC 31722-227-05, and manufacturing details for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc.*

FDA Label Image

7.5-100 (7.5 100)

Label for Meloxicam Tablets USP 7.5 mg by Camber Pharmaceuticals, Inc., containing 100 tablets for oral use. The label includes storage instructions, dosage guidance, manufacturer details, and a barcode, emphasizing pharmacist dispensing of the attached Medication Guide.*

FDA Label Image

7.5-1000 (7.5 1000)

Meloxicam 7.5 mg Tablets USP in oral tablet form, labeled by Camber Pharmaceuticals, Inc. The label indicates the product contains 1000 tablets and includes storage and dispensing instructions. It specifies each tablet contains 7.5 mg of meloxicam and notes the manufacturer as Ascent Pharmaceuticals, Inc., with additional information about the medication guide availability.*

FDA Label Image

7.5-500 (7.5 500)

The label for Meloxicam Tablets USP shows a 7.5 mg oral tablet strength by Camber Pharmaceuticals, Inc. The label includes the NDC 31722-226-05 and states the package contains 500 tablets. It indicates pharmacist instructions, storage conditions, and manufacturing details by Ascent Pharmaceuticals, with dispensing and safety information.*

FDA Label Image

Mg1 (Mg1)

A text panel from meloxicam tablets containing warnings about the use of NSAIDs. It advises against taking NSAIDs before or after coronary artery bypass graft surgery and cautions about increased risk of heart attack following recent heart attack events when taking NSAIDs. The text appears to be part of the drug safety information.*

FDA Label Image

Mg2 (Mg2)

A partial text panel from a Drug Facts or prescribing information document discussing risk factors for ulcers or bleeding. It lists conditions and medication uses that increase risk, such as history of ulcers, use of corticosteroids, anticoagulants, SSRIs, SNRIs, and other factors including older age, poor health, smoking, and drinking alcohol.*

FDA Label Image

Mg3 (Mg3)

Text panel presenting medication guidelines or patient information for Meloxicam tablets. The visible text includes dosage instructions emphasizing adherence to prescribed use, using the lowest effective dose, and limiting treatment duration. The content is part of labeling associated with Meloxicam oral tablets by Camber Pharmaceuticals, Inc.*

FDA Label Image

Mg4 (Mg4)

Drug Facts panel outlining warnings and precautions for meloxicam tablets. It lists serious side effects such as chest pain, shortness of breath, weakness on one side of the body, slurred speech, and swelling of the face or throat.*

FDA Label Image

Mg5 (Mg5)

Text panel listing symptoms and signs related to possible adverse effects or warnings for a medication. The bullet points include nausea, fatigue, diarrhea, itching, jaundice, stomach pain, flu-like symptoms, vomiting blood, blood in bowel movement, unusual weight gain, skin rash or blisters with fever, and swelling of extremities.*

FDA Label Image

Structural (Structural Formula)

Chemical structure diagram of meloxicam, showing its molecular arrangement with sulfur, nitrogen, oxygen atoms, and a methyl group. The structure includes a benzene ring and a thiazole ring, characteristic of meloxicam's chemical composition.*

FDA Label Image

Table 1a (Table 1a)

A data table summarizing adverse events occurring in 2% or more of patients treated with meloxicam 7.5 mg daily, meloxicam 15 mg daily, placebo, or diclofenac 100 mg daily in a 12-week osteoarthritis trial. The table lists counts of patients and percentages of various gastrointestinal, body-wide, central and peripheral nervous system, respiratory, and skin events across the four groups.*

FDA Label Image

Table 1b (Table 1b)

A data table titled 'Adverse Events (%) Occurring in ≥2% of Meloxicam Patients in two 12-Week Rheumatoid Arthritis Placebo-Controlled Trials' comparing placebo with Meloxicam 7.5 mg daily and 15 mg daily groups. It lists the percentage of patients experiencing various adverse events across categories like gastrointestinal disorders, general disorders, infections, musculoskeletal, nervous system, and skin disorders.*

FDA Label Image

Table 2.1 (Table 2.1)

A table listing adverse reactions categorized by body system for meloxicam. It includes detailed side effects under headings like Body as a Whole, Cardiovascular, Central and Peripheral Nervous System, Gastrointestinal, Heart Rate and Rhythm, Hematologic, Liver and Biliary System, Metabolic and Nutritional, Psychiatric, Respiratory, Skin and Appendages, Special Senses, and Urinary System.*

FDA Label Image

Table 2 (Table 2)

A table displaying adverse event percentages occurring in 2% or more of meloxicam patients during 4 to 6 weeks and 6 month active-controlled osteoarthritis trials. It compares effects of meloxicam 7.5 mg and 15 mg daily dosages across gastrointestinal, nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary categories.*

FDA Label Image

Table 3.1 (Table 3.1)

A text panel outlining clinical impacts and interventions when meloxicam is used concomitantly with lithium, methotrexate, cyclosporine, NSAIDs, salicylates, and pemetrexed. It details the potential for increased toxicity and recommendations for patient monitoring or drug administration adjustments.*

FDA Label Image

Table 3 (Table 3)

A data table titled 'Table 3 Clinically Significant Drug Interactions with Meloxicam' summarizing interactions with drugs affecting hemostasis, aspirin, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. The table lists clinical impact and intervention recommendations for each drug category in relation to meloxicam use.*

FDA Label Image

Image Description (Table 4)

A pharmacokinetic data table comparing single dose and steady-state parameters for oral meloxicam at 7.5 mg and 15 mg doses. It includes parameters like Cmax, tmax, t1/2, CL/f, and Vz/f across different populations: healthy male adults, elderly males and females, and patients with renal failure or hepatic insufficiency (fasted).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.